No effects of COVID-19 on the development of type 1 diabetes autoimmunity and no evidence of an increased frequency of SARS-CoV-2 antibodies in newly diagnosed type 1 diabetes patients relative to healthy subjects.
Autoimmunity
COVID-19
SARS-CoV-2
SARS-CoV-2 antibodies
Type 1 diabetes
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
06
10
2022
accepted:
07
01
2023
medline:
23
8
2023
pubmed:
12
5
2023
entrez:
12
5
2023
Statut:
ppublish
Résumé
To evaluate the relationship between SARS-CoV-2 infection and autoimmunity in type 1 diabetes (T1D) and SARS-CoV-2 antibodies frequency at diagnosis of T1D during pandemic. The presence of T1D-specific autoimmunity was evaluated in a cohort of 99 children and adolescents without diabetes that contracted SARS-CoV-2 infection. Moreover, the frequency of IgM- and IgG-SARS-CoV-2 antibodies was evaluated in 41 newly diagnosed T1D patients not yet vaccinated against SARS-CoV-2 disease, collected during the pandemic, compared to healthy subjects (CTRL). None of the 99 patients that contracted SARS-CoV-2 infection during the pandemic period was found positive for T1D autoantibodies. The frequency of SARS-CoV-2 antibodies was not significantly different in patients newly diagnosed with T1D (12.2%), compared with CTRL (8.4%). Among SARS-CoV-2 antibody positive T1D patients, 80% were target of diabetes autoantibodies and 60% had another concomitant autoimmune disease. Among the CTRL subjects positive for SARS-CoV-2Abs (n = 10), none was found positive for T1D autoantibodies. The results of the present study do not confirm, at least in the short term, a role of COVID-19 as a potential trigger of T1D autoimmunity and do not provide evidence of an increased frequency of SARS-CoV-2 antibodies in newly diagnosed T1D patients in comparison with healthy population.
Identifiants
pubmed: 37171699
doi: 10.1007/s00592-023-02103-1
pii: 10.1007/s00592-023-02103-1
pmc: PMC10175916
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1301-1307Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Nenna R, Papoff P, Moretti C et al (2011) Detection of respiratory viruses in the 2009 winter season in Rome: 2009 influenza A (H1N1) complications in children and concomitant type 1 diabetes onset. Int J Immunopathol Pharmacol 24(3):651–659. https://doi.org/10.1177/039463201102400311
doi: 10.1177/039463201102400311
pubmed: 21978697
Lonnrot M, Lynch KF, Elding Larsson H et al (2017) Respiratory infections are temporally associated with initiation of type 1 diabetes autoimmunity: the TEDDY study. Diabetologia 60(10):1931–1940. https://doi.org/10.1007/s00125-017-4365-5
doi: 10.1007/s00125-017-4365-5
pubmed: 28770319
pmcid: 5697762
Unsworth R, Wallace S, Oliver NS et al (2020) New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care 43(11):e170–e171. https://doi.org/10.2337/dc20-1551
doi: 10.2337/dc20-1551
pubmed: 32816997
Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181(2):271–280e278. https://doi.org/10.1016/j.cell.2020.02.052
doi: 10.1016/j.cell.2020.02.052
pubmed: 32142651
pmcid: 7102627
Bornstein SR, Rubino F, Khunti K et al (2020) Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 8(6):546–550. https://doi.org/10.1016/S2213-8587(20)30152-2
doi: 10.1016/S2213-8587(20)30152-2
pubmed: 32334646
pmcid: 7180013
Fang HJ, Yang JK (2010) Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas. J Int Med Res 38(2):558–569. https://doi.org/10.1177/147323001003800218
doi: 10.1177/147323001003800218
pubmed: 20515569
Shoemaker R, Yiannikouris F, Thatcher S, Cassis L (2015) ACE2 deficiency reduces beta-cell mass and impairs beta-cell proliferation in obese C57BL/6 mice. Am J Physiol Endocrinol Metab 309(7):E621–631. https://doi.org/10.1152/ajpendo.00054.2015
doi: 10.1152/ajpendo.00054.2015
pubmed: 26389599
pmcid: 4593774
Ata A, Jalilova A, Kirkgoz T et al (2022) Does COVID-19 predispose patients to type 1 diabetes mellitus? Clin Pediatr Endocrinol 31(1):33–37. https://doi.org/10.1297/cpe.2021-0050
doi: 10.1297/cpe.2021-0050
pubmed: 35002066
Jia X, Gesualdo P, Geno Rasmussen C et al (2021) Prevalence of SARS-CoV-2 antibodies in children and adults with type 1 diabetes. Diabetes Technol Ther 23(7):517–521. https://doi.org/10.1089/dia.2020.0609
doi: 10.1089/dia.2020.0609
pubmed: 33544017
pmcid: 8252893
Salmi H, Heinonen S, Hastbacka J et al (2022) New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. Arch Dis Child 107(2):180–185. https://doi.org/10.1136/archdischild-2020-321220
doi: 10.1136/archdischild-2020-321220
pubmed: 34045208
Tiberti C, Yu L, Lucantoni F et al (2011) Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening. Clin Exp Immunol 166(3):317–324. https://doi.org/10.1111/j.1365-2249.2011.04479.x
doi: 10.1111/j.1365-2249.2011.04479.x
pubmed: 22059988
pmcid: 3232378
Bonamico M, Tiberti C, Picarelli A et al (2001) Radioimmunoassay to detect antitransglutaminase autoantibodies is the most sensitive and specific screening method for celiac disease. Am J Gastroenterol 96(5):1536–1540. https://doi.org/10.1111/j.1572-0241.2001.03754.x
doi: 10.1111/j.1572-0241.2001.03754.x
pubmed: 11374695
Li M, Yu L, Tiberti C et al (2009) A report on the international transglutaminase autoantibody workshop for celiac disease. Am J Gastroenterol 104(1):154–163. https://doi.org/10.1038/ajg.2008.8
doi: 10.1038/ajg.2008.8
pubmed: 19098864
pmcid: 2904747
Falorni A, Chen S, Zanchetta R et al (2011) Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clin Immunol 140(3):291–299. https://doi.org/10.1016/j.clim.2011.04.012
doi: 10.1016/j.clim.2011.04.012
pubmed: 21570358
Coate KC, Cha J, Shrestha S et al (2020) SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in beta cells. Cell Metab 32(6):1028–1040e1024. https://doi.org/10.1016/j.cmet.2020.11.006
doi: 10.1016/j.cmet.2020.11.006
pubmed: 33207245
pmcid: 7664344
Hollstein T, Schulte DM, Schulz J et al (2020) Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat Metab 2(10):1021–1024. https://doi.org/10.1038/s42255-020-00281-8
doi: 10.1038/s42255-020-00281-8
pubmed: 32879473